PMV Pharmaceuticals, Inc. PMVP
1.27 USD +0.06 (+4.96%)
Regular-session close
1.30 +0.03 +2.36%
After hours · Nov 13, 4:00 PM ET
1.19 Day range 1.27
1.02 52-week range 1.80
- YTD
- +1.60%
- 1 year
- -6.62%
News
benzinga.com PMV Pharma Q3 EPS $(0.52) Misses $(0.34) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.34) by 52.94 percent. This is a 30 percent decrease over losses of $(0.40)…
globenewswire.com Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026 Late-breaking oral presentation to highlight efficacy data across tumor types and in the ovarian cancer primary analysis population Late-breaking oral presentation to highlight efficacy data across…
zacks.com PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
seekingalpha.com PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt's 46% response rate and 10-month median duration in Y220C-mutant ovarian cancer. PMVP's medicinal chemistry leverages the…
defenseworld.net PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to Analysts PMV Pharmaceuticals, Inc. (NASDAQ: PMVP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, MarketBeat.com reports. One…
zacks.com Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? PMV Pharmaceuticals, Inc. (PMVP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PMVP's 50-day simple moving average crossed…
benzinga.com PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
benzinga.com Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of…
globenewswire.com PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
globenewswire.com PMV Pharma Announces Proposed Public Offering of Securities PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
globenewswire.com PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
zacks.com PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock? PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
benzinga.com PMV Pharma Q2 EPS $(0.34) Beats $(0.39) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 17.07 percent increase over losses of $(0.41)…
globenewswire.com PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
zacks.com PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5 Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.
benzinga.com PMV Pharma Q1 EPS $(0.34) Beats $(0.39) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is unchanged from the same period last year.- benzinga.com PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today…
globenewswire.com PMV Pharmaceuticals Announces Board Chair Transition Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer,…
benzinga.com PMV Pharma Q4 EPS $(0.34) Beats $(0.41) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.41) by 16.46 percent. This is a 24.44 percent increase over losses of $(0.45)…
globenewswire.com PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com PMV Pharmaceuticals Announces NEJM Publication Showing Phase 1 Rezatapopt Demonstrates Safety And Antitumor Activity In TP53 Y220C–Mutated Cancers PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today…
defenseworld.net PMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Comparison Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and PMV Pharmaceuticals (NASDAQ: PMVP - Get Free Report) are both medical companies, but which is the better business? We will contrast the…- benzinga.com PMV Pharma Q3 EPS $(0.40), Inline PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 8.11 percent decrease over losses of $(0.37) per share from the same period…
benzinga.com PMV Pharmaceuticals Announces Updated Data From The Phase 2 Pivotal Portion Of The Ongoing PYNNACLE Clinical Trial In Patients With Advanced Solid Tumors Harboring A TP53 Y220C Mutation; Overall Response Rate Of 34% (35/103 Patients) Per Investigator Assessment According To Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, Including Confirmed And Unconfirmed Responses Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning…
globenewswire.com PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…- benzinga.com PMV Pharmaceuticals To Present Rezatapopt Pivotal Phase 2 Initial Analysis And Natural History Study Results PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer…
benzinga.com Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types PMV Pharmaceuticals, Inc. PMVP on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors…
benzinga.com Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types PMV Pharma's Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer achieving a 43% response rate in interim results.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com PMV Pharma Announces Interim Data From Phase 2 Pivotal Portion Of PYNNACLE Clinical Trial; Plans To Submit NDA For Platinum Resistant/Refractory Ovarian Cancer By End Of Q1 2027 PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and…
globenewswire.com PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PRINCETON, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
fool.com PMV Pharmaceuticals (PMVP) Q2 Loss Jumps PMV Pharmaceuticals (PMVP) Q2 Loss Jumps- benzinga.com PMV Pharma Q2 EPS $(0.41) Misses $(0.38) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.05 percent. This is a 1950 percent decrease over losses of $(0.02)…
globenewswire.com PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…- benzinga.com PMV Pharma Q1 EPS $(0.34) Beats $(0.37) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 13.33 percent decrease over losses of $(0.30)…
- benzinga.com HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
- benzinga.com PMV Pharma FY 2024 GAAP EPS $(1.14) Misses $(1.08) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.08) by 5.56 percent.
- benzinga.com PMV Pharma Q3 EPS $(0.37) Misses $(0.35) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 8.82 percent decrease over losses of $(0.34)…
benzinga.com HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
benzinga.com PMV Pharma Q2 EPS $(0.02) Beats $(0.33) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.33) by 93.94 percent. This is a 94.74 percent increase over losses of $(0.38)…- benzinga.com Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc.
- benzinga.com Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday's Session Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss.